Novartis pledges $100M to malaria efforts; Lilly, Boehringer outlines new Jardiance kidney trial at Oxford
→ Novartis is dedicating $100 million to fight malaria, committing to advance R&D of next-gen treatments addressing resistance while also implementing a pricing strategy that maximizes access. The commitment follows two decades of involvement in the field, which has built up Novartis’ malaria pipeline that now includes Phase II assets KAF156 and KAE609. The new investment is expected to sustain a global clinical trial program for these assets, as well as other pipeline activities, through 2023.
→ Pivoting to new indications for their SGLT2 diabetes drug, Eli Lilly and Boehringer Ingelheim have signed on University of Oxford researchers to investigate the effects of Jardiance on heart and kidney diseases among patients with chronic kidney disease. Specifically, they want to know how the drug affects the progression of kidney disease and the occurrence of cardiovascular death for diabetics and non-diabetics alike. That’s a slightly different approach from that of rival AstraZeneca, which touted positive data for diabetes patients who happen to have renal problems. Bankrolled by the two pharmas, the new trial — EMPA-KIDNEY — will recruit around 5,000 adults.